The combinatory treatment with TAPI-0 further reduced the % distribution of CD138+ MM cells (4.7% vs. 2.9% in patient 1 and 12.4% vs. 7.9% in patient 2, respectively). This evidence concerns the gene SDC1 and Miyoshi myopathy.